Zydus Cadila, Part Of Cadila Healthcare Group, On Tuesday Said It Has Received Final Approval From The Us Health Regulator To Market Its Generic Version Of Deferasirox Tablets Used In Treatment Of Chronic Iron Overload Due To Blood Transfusions. The Approval By The Us Food And Drug Administration (Usfda) For Deferasirox Tablets Is For Multiple Strengths Of 90 Mg, 180 Mg And 360 Mg, Cadila Healthcare Said In A Regulatory Filing.Deferasirox Binds To Iron And Removes It From The Bloodstream. It Is Used To Treat Iron Overload Caused By Blood Transfusions In Adults And Children Who Are At Least Two Years Old.It Is Also Used To Treat Chronic Iron Overload Syndrome Caused By A Genetic Blood Disorder (Non-Transfusion Dependent Thalassemia) In Adults And Children Who Are At Least 10 Years Old, The Company Said."The Drug Will Be Manufactured At The Group'S Manufacturing Facility At Special Economic Zone, Ahmedabad," It Added. The Group Now Has 291 Approvals And Has So Far Filed Over 390 Abbreviated New Drug Applications Since The Commencement Of The Filing Process In Fy 2003-04.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!